

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Tatsumasa MAE, et al.
SERIAL NO. : 10/752,643
FILED : January 8, 2004
FOR : LIGAND FOR PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTOR
GROUP ART UNIT : 1654
EXAMINER : Susan D. COE

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

S I R:


In response to the Restriction Requirement mailed May 13, 2005, Applicants elect with traverse Group II for examination, which includes claims 11, 14, 17, and 20, drawn to a method for preventing and/or treating insulin resistance syndrome.

Applicants submit that Groups II, III, and IV are related because diabetes mellitus and visceral fat obesity are kinds of insulin resistance syndrome, as described in the specification, paragraph 004, for example, which states "PPAR γ ligands are also useful for prevention and/or improvement of Insulin Resistance Syndrome, not only for type-II diabetes mellitus but also for ... obesity,..., due to its ability to improve insulin resistance." Accordingly, Applicants request that the Restriction Requirement be withdrawn with respect to at least Groups II, III, and IV, and that these Groups be examined together.

The Examiner is invited to call the undersigned at (202) 220-4200 to discuss any information concerning this application. The Office is hereby authorized to charge any fees or credit any overpayment to Deposit Account No. 11-0600.

Respectfully submitted,

Date: June 13, 2005



Cassandra T. Swain, Ph.D.
Registration No. 48,361

KENYON & KENYON
1500 K Street, NW, Suite 700
Washington, D.C. 20005-1257
Tel.: (202) 220-4200
Fax.: (202) 220-4201